TargetBeta
PKLR
pyruvate kinase L/R · Pyruvate kinase family
2 programs in company-led studies act on PKLR, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| mitapivatrule | Agios Pharmaceuticals | phase 4 | 2410 running | – | ChEMBL |
| etavopivat | Novo Nordisk | phase 3 | 124 running | – | a judged reading |
Conditions their studies are in
- Anemia, 2 programs
- Anemia, Sickle Cell, 2 programs
- Thalassemia, 2 programs
- Anemia, Hemolytic, 1 program
- beta-Thalassemia, 1 program
- Liver Diseases, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Aug 20, 2027etavopivat · Novo Nordisk · phase 3 · NCT05953584
- Mar 2029mitapivat · Agios Pharmaceuticals · phase 4 · NCT07517133
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.